Assessing the impact of multiple sclerosis disease activity and daclizumab HYP treatment on patient-reported outcomes: Results from the SELECT trial. Phillips G, Guo S, Bender R, Havrdová E, Proskorovsky I, Vollmer T Mult Scler Relat Disord. 2016 Mar; 6:66-72. Epub 2016 Feb 01. PMID: 27063626. Abstract CommentRecommendBookmarkWatch